FINWIRES · TerminalLIVE
FINWIRES

Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer

By

Alpha Tau Medical (DRTS) said Monday that data from a pooled analysis of three prospective phase 1/2 trials of its Alpha DaRT device to treat advanced pancreatic cancer, exceeded the overall survival and safety rate compared with standard second-line chemotherapy.

The oncology company said the data came from a pooled analysis of the clinical studies, which are evaluating endoscopic ultrasound-guided intratumoral Alpha DaRT treatment in patients who have locally advanced or metastatic pancreatic ductal adenocarcinoma.

Alpha DaRT-treated patients who have already received two lines of chemotherapy had a median overall survival of 17.1 months in locally advanced disease, and 11.3 months in metastatic disease, the company said. This is compared with approximately nine months for and four to six months respectively for standard second-line chemotherapies, Alpha Tau Medical said.

Price: $10.52, Change: $-0.31, Percent Change: -2.86%

Related Articles

Wire

PolyPid Completes Rolling NDA Submission to FDA for D-PLEX100

PolyPid (PYPD) has completed its rolling new drug application submission to the US Food and Drug Administration for D-PLEX100 for the prevention of surgical site infections in patients undergoing colorectal surgery, the company said Monday.The company said it expects a potential FDA decision in Q1 2027 under the Prescription Drug User Fee Act review timeline.The submission is backed by data from a Phase 3 trial in which D-PLEX100 met its primary and all key secondary endpoints, and reduced surgical site infection risk by 60% compared with standard of care, PolyPid said.Price: $4.74, Change: $+0.02, Percent Change: +0.32%

$PYPD
Wire

Sensata Technologies, Subsidiaries Raise Maximum Amount for Senior Note Tender Offers to $400 Million

Sensata Technologies (ST) and its subsidiaries Sensata Technologies BV, or STBV, and Sensata Technologies Inc., or STI, have increased the maximum tender offer amount for its cash tender offers for three series of notes to $400 million from $350 million, they said Monday.The note series are STBV's 4.000% senior notes due 2029, STI's 4.375% senior notes due 2030, and STBV's 5.875% senior notes due 2030.At the early tender deadline of May 29, the tenders of STBV's 2029 notes amounted to around $553.6 million, exceeding the maximum tender offer amount. The subsidiary expects to accept for purchase STBV 2029 notes up to the maximum of $400 million, as the series had the highest level of priority as stipulated in the purchase offer.The purchase of the STBV 2029 notes will be prorated in accordance with the terms of the applicable tender offer at a rate of more than 69%, and STBV expects to make payments on the early settlement date on Tuesday, according to the statement.Price: $49.20, Change: $-0.20, Percent Change: -0.40%

$ST
Wire

Anixa Biosciences Says Canadian IP Office Issues Notice of Allowance for Patent Covering Ovarian Cancer Vaccine Technology

Anixa Biosciences (ANIX) said Monday that the Canadian Intellectual Property Office has issued a notice of allowance for a patent covering the company's ovarian cancer vaccine technology.The patent, exclusively licensed from Cleveland Clinic, includes methods of administering an immunogenic composition comprising a nucleic acid encoding the anti-Mullerian hormone receptor 2 polypeptide, the company said.Price: $2.72, Change: $+0.02, Percent Change: +0.74%

$ANIX